Status:
COMPLETED
Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction
Lead Sponsor:
Al-Azhar University
Conditions:
PCOS (Polycystic Ovary Syndrome)
Eligibility:
FEMALE
18-40 years
Phase:
NA
Brief Summary
Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disorders in women of reproductive age. According to the World Health Organization (WHO) estimation revealed over 116 million women (3.4...
Detailed Description
In women with PCOS, the serum FSH levels are slightly lower during the follicular phase, therefore aromatization of excessive androgens is insufficient, and the follicles will not undergo the final FS...
Eligibility Criteria
Inclusion
- Women diagnosed with PCOS according to Rotterdam criteria (Rotterdam, 2004) as:
- Menstrual anomalies like amenorrhea (no cycles in the past 6 months), oligomenorrhoea (cycles lasting longer than 35 days), or long cycles.
- Clinical and/or biochemical hyperandrogenism.
- Ultrasound (USG) appearance of polycystic ovaries (multiple cysts \>12 in number of 2-9 mm size).
Exclusion
- Patient with liver and kidney disease.
- Congenital adrenal hyperplasia.
- Hypothalamic or pituitary cause of amenorrhea.
- Primary hyperprolactinemia.
Key Trial Info
Start Date :
January 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 10 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07168837
Start Date
January 10 2023
End Date
May 10 2024
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Azhar University Hospitals
Asyut, Egypt